Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Therapy for AML with Myelodysplasia-Related Changes (AML-MRC)

Taiichi Kyo, MD, Kouhei Kyo, MD, Takeshi Okatani, MD, Tetsuro Ochi, MD, Kayo Toishigawa, Ryota Imanaka, MD, Yuta Katayama, MD PhD, Mitsuhiro Itagaki, MD

Blood (2015) 126 (23): 1340.

https://doi.org/10.1182/blood.V126.23.1340.1340

Published: 2015

Journal Articles

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Ryota Imanaka, MD, Taiichi Kyo, MD, Kayo Toishigawa, MD, Tetsuro Ochi, MD, Takeshi Okatani, MD, Kouhei Kyo, MD, Mitsuhiro Itagaki, MD, Hisao Nagoshi, MD, Yuta Katayama, MD PhD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2015) 126 (23): 2500.

https://doi.org/10.1182/blood.V126.23.2500.2500

Published: 2015

Journal Articles

Treatment of AML with Myelodysplasia Related Changes(AML-MRC) By Sequential Therapy of Azacitidine (AZA) and Intensive Chemotherapy

Taiichi Kyo, MD, Kouhei Kyo, MD, Kayo Toishikawa, MD, Ryota Imanaka, MD, Tetsuro Ochi, MD, Yuta Katayama, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2014) 124 (21): 5288.

https://doi.org/10.1182/blood.V124.21.5288.5288

Published: 2014

Journal Articles

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Taiichi Kyo, M.D., Kouhei Kyo, MD, Ryouta Imanaka, M.D., Mitsuhiro Itagaki, MD, Tetsuro Ochi, Takeshi Okatani, M.D., Koji Iwato, MD, Yuta Katayama, MD, PhD, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 1571.

https://doi.org/10.1182/blood.V122.21.1571.1571

Published: 2013

Journal Articles

Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)

Taiichi Kyo, MD, Noriaki Yoshida, MD, Kouhei Kyo, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Hiromi Yuasa, MD, Koji Iwato, MD, Hideki Asaoku, MD, Yuuta Katayama, MD

Blood (2010) 116 (21): 2934.

https://doi.org/10.1182/blood.V116.21.2934.2934

Published: 2010

Journal Articles

High Remission Rates and Long-Term Survival in a High Percentage of Patients Achieved by Intensive Chemotherapy for AML and Further Improvement of Supportive Care.

Taiichi Kyo, MD, Akiko Kimura, MD, Kouhei Kyo, MD, Noriaki Yoshida, MD, Hideki Asaoku, MD, Koji Iwato, MD, Yuuta Katayama, MD, Hiromi Yuasa, MD

Blood (2009) 114 (22): 1052.

https://doi.org/10.1182/blood.V114.22.1052.1052

Published: 2009

NARROW

Therapy for AML with Myelodysplasia-Related Changes (AML-MRC)

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Treatment of AML with Myelodysplasia Related Changes(AML-MRC) By Sequential Therapy of Azacitidine (AZA) and Intensive Chemotherapy

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)

High Remission Rates and Long-Term Survival in a High Percentage of Patients Achieved by Intensive Chemotherapy for AML and Further Improvement of Supportive Care.

Email alerts

ASH Publications

American Society of Hematology

Therapy for AML with Myelodysplasia-Related Changes (AML-MRC)

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Treatment of AML with Myelodysplasia Related Changes(AML-MRC) By Sequential Therapy of Azacitidine (AZA) and Intensive Chemotherapy

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)

High Remission Rates and Long-Term Survival in a High Percentage of Patients Achieved by Intensive Chemotherapy for AML and Further Improvement of Supportive Care.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only